Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)

Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers.

Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter.

On the other hand, Livdelzi, a PPARδ agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.

Also, despite ongoing weakness in demand for the COVID-19 antiviral Veklury, Gilead raised its full-year 2026 product sales guidance from $30-$30.4 billion to $30.1-$30.4 billion.

In this article, I explain why I'm upgrading my Gilead rating from 'Hold' to 'Buy'.

Six days ago, on August 4, Gilead Sciences ( GILD ) released its Q2 earnings report. It showed higher sales growth rates for its HIV franchise, Livdelzi, and Trodelvy than I had projected under my 'base case' scenario.

Overall, Gilead's revenue was This article was written by ALLKA Research 3.52K Followers Follow With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Research thrives on simplifying investment strategies, ensuring accessibility for both seasoned investors and those just starting.Driven by an unwavering passion for empowering others financially, Allka Research seeks to share its wealth of knowledge through Seeking Alpha. Its mission is to contribute thought-provoking analyses and informed perspectives to the Seeking Alpha community. With a desire to demystify the intricacies of investing, Allka Research aims to inspire confidence in its readers, fostering a community of informed investors who can navigate the markets with intelligence and understanding. Join Allka Research on this exciting journey of discovery and wealth creation as it continues to unravel the secrets of the financial world on Seeking Alpha. Analyst’s Disclosure: I/we have a beneficial long position in the shares of LEGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.